ImmunityBio Chief Executive Officer Richard Adcock acknowledges the frustration with how long it’s taken getting the Dunkirk ...

ImmunityBio (IBRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

The stalled Dunkirk pharmaceutical project is moving ahead with a new lease for ImmunityBio and tighter controls.

ImmunityBio has secured final local approval to restart its long-delayed Dunkirk, New York manufacturing facility, set to become a key U.S. hub for its cancer immunotherapy Anktiva. The project ...

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ImmunityBio, Inc. is one of the best ...

ImmunityBio has now commercially launched its immunotherapy ANKTIVA in Saudi Arabia for approved bladder and metastatic non-small cell lung cancer indications, with distribution supported by regional ...

ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and ...

Explore ImmunityBio’s recent market movement, biotech sector trends, and key factors shaping its outlook in a dynamic ...

View ImmunityBio Inc IBRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

ImmunityBio finds itself navigating a stark divergence between its commercial success and a burgeoning legal crisis. While the biotech firm reports record-breaking revenue for its cancer drug Anktiva, ...

Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of ...

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information ...